About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Intuitive Surgical, Inc. (ISRG) is a Healthcare company in the Medical Instruments & Supplies industry with a market capitalisation of $129.1B. The stock trades at 40.50x trailing earnings.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $129.1B
- P/E ratio
- 40.50
- Forward P/E
- 29.86
- EPS (TTM)
- $8.90
- Revenue (TTM)
- $11B
- Free cash flow
- $2.6B
- Profit margin
- 28.4%
- Beta
- 1.47
- Shares outstanding
- 358.3M
Financial health: Strong9.4/10
7 strengths, 0 concerns. No red flags against these benchmarks.
- Current ratio: 4.87 (Strong, benchmark > 1.5) — Short-term assets cover 4.87x short-term liabilities, against Graham's 1.5x floor. It has improved over the last 4 years.
- Return on equity: 17.4% (Strong, benchmark > 15%) — Earns 17.4% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 66.7% (Strong, benchmark > 40%) — Keeps 66.7% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 28.4% (Strong, benchmark > 10%) — Turns 28.4% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $2.5B (Strong, benchmark positive) — Generated $2.5B of free cash flow after capital spending. It has improved over the last 4 years.
- Revenue growth: 18.5% (Strong, benchmark > 10%) — Revenue changed 18.5% year on year, comfortably past the > 10% mark.
- Earnings growth: 26.5% (Strong, benchmark > 10%) — Earnings changed 26.5% year on year, comfortably past the > 10% mark.
- PEG ratio: 1.64 (Watch, benchmark < 1) — At 1.64, the price looks fair relative to expected growth — Lynch treated 1.0 as fair value.